title: High prevalence of extended-spectrum beta-lactamases and plasmid-mediated AmpC beta-lactamases in Enterobacteriaceae isolated from long-term care facilities in Korea.
abstract: The aim of this study was to investigate for the first time the prevalence and types of extended-spectrum beta-lactamase (ESBL) and plasmid-mediated AmpC beta-lactamase (PABL) in Enterobacteriaceae in Korean long-term care facilities (LTCFs). ESBL rates were 45.3% (72/159) in Escherichia coli and 42.7% (50/117) in Klebsiella pneumoniae. In E. coli, CTX-M-28, the most prevalent ESBLs, was identified for the first time in Korea in 44 isolates. In K. pneumoniae, SHV-12 was found in 27 isolates (52.9% of ESBLs), among which 25 isolates also contained SHV-11. Twenty-seven isolates had SHV and CTX-M beta-lactamase simultaneously. PABL genes were detected in 39.3% (46/117) of K. pneumoniae and 3.1% (5/159) E. coli. In E. coli, DHA-1(3), CMY-2(1), and CMY-6(1) were detected, whereas in K. pneumoniae, only DHA-1 was detected. Among the PABL-producing organisms, 80.0% (E. coli) and 52.2% (K. pneumoniae) simultaneously produced ESBLs. In conclusion, LTCF residents in Korea have a very high prevalence of E. coli and K. pneumoniae producing ESBLs, PABLs, or both, and the genotypes of ESBL and PABL were identical with those found in general hospitals.
authors.affiliation: Division of Antimicrobial Resistance, Center for Infectious Disease Research, National Institute of Health Korea, Korea Centers for Disease Control and Prevention, Seoul, Republic of Korea.
authors.forename: Jung Sik
authors.initials: JS
authors.lastname: Yoo
authors.forename: Jeonghum
authors.initials: J
authors.lastname: Byeon
authors.forename: Jiwoo
authors.initials: J
authors.lastname: Yang
authors.forename: Jae Il
authors.initials: JI
authors.lastname: Yoo
authors.forename: Gyung Tae
authors.initials: GT
authors.lastname: Chung
authors.forename: Yeong Seon
authors.initials: YS
authors.lastname: Lee
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology; D001426:Bacterial Proteins / Q000096:biosynthesis* / Q000145:classification / Q000235:genetics; D003428:Cross Infection / Q000382:microbiology; D017931:DNA Primers / Q000235:genetics; D004269:DNA, Bacterial / Q000235:genetics; D004926:Escherichia coli / Q000187:drug effects / Q000201:enzymology* / Q000302:isolation & purification; D004927:Escherichia coli Infections / Q000382:microbiology*; D006801:Humans; D007710:Klebsiella Infections / Q000382:microbiology*; D007711:Klebsiella pneumoniae / Q000187:drug effects / Q000201:enzymology* / Q000302:isolation & purification; D008134:Long-Term Care; D008826:Microbial Sensitivity Tests; D016133:Polymerase Chain Reaction / Q000379:methods; D015995:Prevalence; D056910:Republic of Korea; D001618:beta-Lactamases / Q000096:biosynthesis* / Q000145:classification / Q000235:genetics
chemical_list: D000900:Anti-Bacterial Agents; D001426:Bacterial Proteins; D017931:DNA Primers; D004269:DNA, Bacterial; D001618:beta-Lactamases